171 related articles for article (PubMed ID: 11100886)
21. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma.
Barillé S; Bataille R; Amiot M
Eur Cytokine Netw; 2000 Dec; 11(4):546-51. PubMed ID: 11125296
[TBL] [Abstract][Full Text] [Related]
22. Role of cytokines in multiple myeloma.
Anderson KC; Lust JA
Semin Hematol; 1999 Jan; 36(1 Suppl 3):14-20. PubMed ID: 9989484
[TBL] [Abstract][Full Text] [Related]
23. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
24. Role of stromal-derived cytokines and growth factors in bone metastasis.
David Roodman G
Cancer; 2003 Feb; 97(3 Suppl):733-8. PubMed ID: 12548570
[TBL] [Abstract][Full Text] [Related]
25. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
[TBL] [Abstract][Full Text] [Related]
26. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation.
Kanazawa S; Tsunoda T; Onuma E; Majima T; Kagiyama M; Kikuchi K
Am J Gastroenterol; 2001 Mar; 96(3):822-8. PubMed ID: 11280558
[TBL] [Abstract][Full Text] [Related]
27. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC
Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984
[TBL] [Abstract][Full Text] [Related]
28. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells.
Benckert C; Jonas S; Cramer T; Von Marschall Z; Schäfer G; Peters M; Wagner K; Radke C; Wiedenmann B; Neuhaus P; Höcker M; Rosewicz S
Cancer Res; 2003 Mar; 63(5):1083-92. PubMed ID: 12615726
[TBL] [Abstract][Full Text] [Related]
29. The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma.
Ehrlich LA; Roodman GD
Immunol Rev; 2005 Dec; 208():252-66. PubMed ID: 16313353
[TBL] [Abstract][Full Text] [Related]
30. [Bone-derived growth factors and cytokines].
Yoshikawa H; Hashimoto J; Takaoka K
Nihon Rinsho; 1990 Dec; 48(12):2818-22. PubMed ID: 2086839
[No Abstract] [Full Text] [Related]
31. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.
Dankbar B; Padró T; Leo R; Feldmann B; Kropff M; Mesters RM; Serve H; Berdel WE; Kienast J
Blood; 2000 Apr; 95(8):2630-6. PubMed ID: 10753844
[TBL] [Abstract][Full Text] [Related]
32. Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells.
Vincent L; Jin DK; Karajannis MA; Shido K; Hooper AT; Rashbaum WK; Pytowski B; Wu Y; Hicklin DJ; Zhu Z; Bohlen P; Niesvizky R; Rafii S
Cancer Res; 2005 Apr; 65(8):3185-92. PubMed ID: 15833849
[TBL] [Abstract][Full Text] [Related]
33. [Kinetics of inflammatory cytokines during hyperacute phase of ischemic stroke].
Yahikozawa H; Hagiwara N; Ikeda S
Nihon Rinsho; 2006 Oct; 64 Suppl 7():166-70. PubMed ID: 17461145
[No Abstract] [Full Text] [Related]
34. Immunohistochemical expression of angiogenic cytokines and their receptors in reactive benign lymph nodes and non-Hodgkin lymphoma.
Ho CL; Sheu LF; Li CY
Ann Diagn Pathol; 2003 Feb; 7(1):1-8. PubMed ID: 12616467
[TBL] [Abstract][Full Text] [Related]
35. [Modulation of mu-PA gene expression by inflammatory cytokines in RC-K8 lymphoma cells].
Niiya K
Rinsho Byori; 1997 Feb; Suppl 104():150-8. PubMed ID: 9128376
[No Abstract] [Full Text] [Related]
36. Recruitment of mononuclear cells into wounded skin: mechanism and modulation.
Cai JP; Harris B; Falanga V; Eaglstein WH; Mertz PM; Chin YH
Prog Clin Biol Res; 1991; 365():243-56. PubMed ID: 1862136
[TBL] [Abstract][Full Text] [Related]
37. FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma.
Kumar S; Raje N; Hideshima T; Ishitsuka K; Podar K; Le Gouille S; Chauhan D; Richardson P; Munshi NC; Anderson K
Br J Haematol; 2006 Mar; 132(6):698-704. PubMed ID: 16487170
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of erythroblast apoptosis by malignant plasma cells: a new pathogenetic mechanism of anemia in multiple myeloma.
Silvestris F; Cafforio P; Grinello D; Dammacco F
Rev Clin Exp Hematol; 2002; Suppl 1():39-46. PubMed ID: 12735214
[TBL] [Abstract][Full Text] [Related]
39. Role of different cytokines and seizure susceptibility: a new dimension towards epilepsy research.
Rao RS; Prakash A; Medhi B
Indian J Exp Biol; 2009 Aug; 47(8):625-34. PubMed ID: 19775068
[TBL] [Abstract][Full Text] [Related]
40. Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells.
Li M; Cortez S; Nakamachi T; Batuman V; Arimura A
Cancer Res; 2006 Sep; 66(17):8796-803. PubMed ID: 16951196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
